Absstract of: WO2020260722A1

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

Absstract of: US2023129819A1

The present invention relates to a preparation method for an animal model with Alzheimer's disease by injecting a human mutant tau (AAV-hTau) vector and adenovirus into an animal. The preparation method for an AD animal model provided by the present invention may contribute to the development of the field of treatment technology for treating AD since the preparation method causes AD pathology to appear as early as 8 months old and facilitates studies on AD target treatment strategies and tau pathology.

Absstract of: US2020109192A1

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Absstract of: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

Absstract of: US2023125690A1

The present invention relates to an antibody for detecting acetylation of COX2 protein, and uses thereof, and more specifically, to an antibody that specifically recognizes the acetylation of S565 residue of the COX2 protein; and uses thereof for diagnosing neurodegenerative diseases or inflammatory diseases. An antibody or a functional fragment thereof according to the present invention specifically binds to an acetylated residue of COX2 protein, and can thus be very effectively used for diagnosing neurodegenerative diseases, inflammatory diseases, and the like in which the degree of acetylation of S565 residue of the COX2 protein is reduced.

Absstract of: US2023126858A1

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Absstract of: US2023130218A1

The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Absstract of: KR20230054238A

본 발명은 PLC 활성제를 유효성분으로 포함하는 알츠하이머 치매 예방 또는 치료용 조성물 등에 관한 것이다. 본 발명의 PLC 활성제를 유효성분으로 포함하는 조성물은 AβO에 의해 억제된 S-eCB 동원을 복원시키고, AβO로 손상된 시냅스 가소성을 회복시키며, AβO 처리 마우스 해마 절편 및 AD 만성 단계의 5XFAD 마우스 해마 절편에서 PLCβ1 단백질 수준을 정상으로 회복시킬 뿐만 아니라, AD 마우스에서 맥락적 공포 기억 손상을 회복시키는 바, 알츠하이머 치매의 예방 또는 치료에 유용하게 사용 가능할 것으로 기대된다.

Absstract of: US2023119699A1

The present disclosure relates to the use of SIRT1 expression to identify a subject that is conducive to treatment with a miR-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced SIRT1 expression. In some aspects, the SIRT1 expression is measured in the serum of the subject.

Absstract of: US2023121720A1

The present disclosure relates to the use of PGC-1α expression to identify a subject that is conducive to treatment with a ma-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced PGC-1α expression. In some aspects, the PGC-1α expression is measured in the serum of the subject.

Absstract of: US2023123110A1

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

Absstract of: US2023117859A1

The present disclosure provides treatments for neurodegenerative disorders and more particularly to methods for treatment of patients with Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), or Alzheimer's disease of different degrees of severity. The methods for treatment of patients who have suffered neurodegenerative diseases and specifically MS, ALS, or Alzheimer's disease includes administering a xenon gas mixture in subjects with elevated levels of neurodegenerative microglia (MGnD), e.g., determined based on levels of inflammatory biomarkers, measured in blood, serum and CSF, or levels of CLEC7A (Dectin-1)/Translocator Protein (TSPO) expression, e.g., measured using TSPO imaging.

Absstract of: US2023118869A1

The present invention relates to a composition for preventing or treating Alzheimer’s disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer’s disease.

Absstract of: WO2023064794A1

Systems, apparatuses and methods for prophylactically preventing, or for treating the onset and/or progression of Cerebral Amyloid Angiopathy (CAA), acute stroke conditions, or Alzheimer's disease include the administration to a patient pre-beta HDL particles, a CETP inhibitor, or a combination of both pre-beta HDL particles and a CETP inhibitor. The progression of, stabilizing, or improving symptoms related to these conditions are treated by monitoring a pathophysiological change indicative of the conditions in a patient, based on the monitoring, determining if amyloid plaque is present in a perivascular space/l PAD System/Perivascular Pathway of the patient, optionally determining an extent of amyloid plaque in the perivascular space/IPAD System/Perivascular Pathway, and based on the presence of amyloid plaque in the perivascular space/IPAD System/Perivascular Pathway of the patient, determining a treatment protocol for the patient.

Absstract of: WO2021255027A1

The present invention relates to a sorLA-based drug screening platform for use in screening compound libraries for an effect on endosomal activity.

Absstract of: WO2021170752A1

The present invention is directed to a method for diagnosis or prognosis of a disease in a subject and/or predicting a risk of getting a disease or adverse event in a subject and/or monitoring a disease or adverse event in a subject by determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or its isoforms and/or fragments thereof in a sample of bodily fluid of said subject.

Absstract of: WO2023057875A1

Method for the early diagnosis and the monitoring of the evolution/regression of neurodegenerative pathologies, said method providing for the quantification of a. biomarker for said pathologies in a fluid that was previously drawn from a. patient, said fluid being selected from among: cerebrospinal fluid; serum; urine; post mortem cerebral tissues and cellular lysates, said method being characterized in that the quantified biomarker is selected from among native proNGF; modified proNGF, the latter being proNGF in its forms with higher molecular weight, including forms of 39-40 kDa and 45-50kDa; NGF; and the proNGF/NGF ratio, said method sequentially providing for the fol lowing steps of Preparation of the biological sample, Definition of the calibration curve; Execution of run and interpolation.

Absstract of: WO2021165465A1

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

Absstract of: US2023111650A1

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods involve the steps of (a) culturing lymphocytes from the subject under suitable conditions; (b) measuring the amount of PKCε in the cultured lymphocytes; and (c) comparing the measurement of step (b) with a suitable control.

Absstract of: US2023111145A1

Among the various aspects of the present disclosure is the provision of detecting proteins associated with Alzheimer's disease (AD) or risk variant thereof; diagnosis, prognosis, and monitoring of disease progression; or monitoring treatment.

Absstract of: WO2023058627A1

In order to identify a blood biomarker molecule that makes it possible to distinguish between a dementia patient and a healthy subject and provide a dementia testing method that uses the quantity of said molecule as an indicator, the ECRG4 positivity rate and concentration was detected in blood plasma of dementia patients, patients with mild cognitive impairment, and non-dementia patients or the like. As results, although ECRG4 was detected in the blood plasma of 50% of dementia patients and patients with mild cognitive impairment, ECRG4 was not detected in 95% of the non-dementia patients. It was also discovered that the blood plasma level of ECRG4 in dementia patients and MCI patients was far higher than in non-dementia patients, and ECRG4 is extremely effective as a blood biomarker molecule for dementia.

Absstract of: US2023106874A1

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

Absstract of: WO2023052742A1

The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.

Absstract of: EP4159223A1

The present invention relates to a pharmaceutical composition comprising an agent inhibiting gene expression or protein activity of osteopontin as an active ingredient for preventing or treating neurodegenerative disease. According to the present invention, there is an effect of suppressing amyloid beta (Aβ)-induced neuronal cell death by downregulating the expression or activity of osteopontin. In addition, an inhibitor against the expression or activity of osteopontin decreases a level of pro-inflammatory proteins and conversely, increases a level of anti-inflammatory proteins. Therefore, it is expected that the present invention can be advantageously used as a therapeutic agent for various neurodegenerative diseases including Alzheimer's disease.

Absstract of: US2022034912A1

The present invention refers to p53 sequence and post translational modifications (PTMs) and to their use as biomarkers in the diagnosis of neurodegenerative disease and cognitive decline and/or in the prognosis of Alzheimer's disease at different stages and/or of neurodegenerative disease in a biological sample. The invention also provides for a 1) diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of neurodegenerative disease, including Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), fronto-temporal dementia (FTD), Lewi's Body (LB), and vascular dementia (VD) in a subject, by evaluating the PTMs to the said p53 linear sequence protein and possible cut of its full sequence specifically in human plasma of patients; and 2) prognosis of AD in CU and MCI patients.